RDB12876 - CSIV-TRE-RfA-CMV-KT

CSIV-TRE-RfA-CMV-KT (#RDB12876)

Backbone vector plasmid of lentivirus construct driven by Tet-responsive promoter by Gateway(R) cloning with hKO1-2A-rtTA marker driven by CMV promoter.

Drawn by SnapGene® software

Sequence information (Assembled from experimentally sequenced data)	GenBank Flat File Format open
	SnapGene file download
Publication	Isaji, T., J. Biol. Chem. 289 (30): 20694-20705 (2014). PMID 24895123. [PubMed] [Article] [RRC of NBRP]
Test sheet	Data Sheet open

Clone info.	Backbone vector plasmid of lentivirus construct driven by Tet-responsive promoter by Gateway(R) cloning with hKO1-2A-rtTA marker driven by CMV promoter.
Comment	pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging.
Vector backbone	Plasmid
Selectable markers	Ampicillin, Chloramphenicol, ccdB (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Growth remarks	Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30℃ is fine.
Depositor\|Developer	Miyoshi, Hiroyuki \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link]

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).

Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.

Remarks Remember that you will be working with samples containing infectious virus.
Use Survival2 (Invitrogen) or equivalent to amplify this clone.
Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Ordering instruction.[link]
Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004). Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.
Remarks	Remember that you will be working with samples containing infectious virus. Use Survival2 (Invitrogen) or equivalent to amplify this clone. Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。付加的使用条件： When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004). InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。
備考	このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。このクローンの増殖にはSurvival2 (Invitrogen)あるいは同等の宿主を使用してください。 ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。

Catalog #	Resource name	Shipping form	Fee
RDB12876	CSIV-TRE-RfA-CMV-KT	DNA solution

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSIV-TRE-RfA-CMV-KT was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB12876).

Reference section:

Isaji, T., Im, S., Gu, W., Wang, Y., Hang, Q., Lu, J., Fukuda, T., Hashii, N., Takakura, D., Kawasaki, N., Miyoshi, H., Gu, J., An oncogenic protein Golgi phosphoprotein 3 up-regulates cell migration via sialylation. J. Biol. Chem. 289 (30): 20694-20705 (2014). PMID 24895123. [PubMed] [Article] [RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

original	Isaji, T., An oncogenic protein Golgi phosphoprotein 3 up-regulates cell migration via sialylation. J. Biol. Chem. 289 (30): 20694-20705 (2014). PMID 24895123. [PubMed] [Article] [RRC of NBRP]
reference	Umei, T.C., Single-Construct Polycistronic Doxycycline-Inducible Vectors Improve Direct Cardiac Reprogramming and Can Be Used to Identify the Critical Timing of Transgene Expression. Int. J. Mol. Sci. 18 (8). pii: E1805 (2017). PMID 28825623. [PubMed] [Article]
reference	Lu, J., Expression of N-Acetylglucosaminyltransferase III Suppresses α2,3-Sialylation, and Its Distinctive Functions in Cell Migration Are Attributed to α2,6-Sialylation Levels. J. Biol. Chem. 291 (11): 5708-5720 (2016). PMID 26801611. [PubMed] [Article]
reference	Tai, M.C., miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis 36 (12): 1464-1473 (2015). PMID 26483346. [PubMed] [Article] [RRC of NBRP]
reference	Chapnick, D.A., Leader cell positioning drives wound-directed collective migration in TGFβ-stimulated epithelial sheets. Mol. Biol. Cell, 25 (10): 1586-1593 (2014). PMID 24623725. [PubMed] [Article] [RRC of NBRP]
reference	Kurita, R., Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One 8 (3): e59890 (2013). PMID 23533656. [PubMed] [Article] [RRC of NBRP]
user_report	Yamada, N., Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis. Nat Commun. 2024 Mar 12;15(1):2195 PMID 38472233. [PubMed] [Article] [RRC of NBRP]
user_report	Zhang, H., The maturation of iPS cell-derived brain microvascular endothelial cells by inducible-SOX18 expression. Fluids Barriers CNS 20 (1): 10 (2023). PMID 36732767. [PubMed] [Article] [RRC of NBRP]
user_report	Zhang, H., Transient ETV2 Expression Promotes the Generation of Mature Endothelial Cells from Human Pluripotent Stem Cells. Biol. Pharm. Bull. 45 (4): 483-490 (2022). PMID 35370273. [PubMed] [Article] [RRC of NBRP]
user_report	Orimoto, A., Establishment of human airway epithelial cells with doxycycline-inducible cell growth and fluorescence reporters. Cytotechnology 73 (4): 555-569 (2021). PMID 34349346. [PubMed] [Article] [RRC of NBRP]
user_report	Ito, N., Direct reprogramming of fibroblasts into skeletal muscle progenitor cells by transcription factors enriched in undifferentiated subpopulation of satellite cells. Sci. Rep. 7 (1): 8097 (2017). PMID 28808339. [PubMed] [Article] [RRC of NBRP]

Resource search

Link

Other resources in our bank

External Database

Reference sequence